GlassScriptPhysician profile
Nicholas Tieu
NPI 1265203889
$4,752.44
in general payments reported to CMS, 2019-2025
30 companies · $3,098 in 2025
The $3,098 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,654 · 2025: $3,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,475 · Education: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,475.08 |
| Education | $277.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $967.38 | 2024-2025 | Enhertu, Datroway, Injectafer |
| Sobi, INC | $392.53 | 2024-2025 | |
| Exelixis INC. | $367.54 | 2024-2025 | Cabometyx |
| Astrazeneca Pharmaceuticals LP | $344.76 | 2024-2025 | Imfinzi, Calquence |
| Beone Medicines USA, INC. | $234.61 | 2025 | Tevimbra, Brukinsa |
| Merck Sharp & Dohme LLC | $215.97 | 2024-2025 | Keytruda, Keytruda Qlex, Welireg |
| Servier Pharmaceuticals LLC | $201.07 | 2024-2025 | Voranigo |
| Regeneron Healthcare Solutions, INC. | $165.24 | 2024 | Libtayo |
| Novartis Pharmaceuticals Corporation | $163.48 | 2025 | |
| Lilly USA, LLC | $153.90 | 2024-2025 | Verzenio, Jaypirca |
| Pfizer INC. | $143.54 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $129.82 | 2024 | Reblozyl |
| Karyopharm Therapeutics INC. | $127.98 | 2024-2025 | Xpovio |
| Genentech USA, INC. | $109.63 | 2024-2025 | Tecentriq, Kadcyla, Lunsumio |
| Array Biopharma INC | $105.57 | 2024-2025 | Lorbrena, Braftovi, Mektovi |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $88.52 | 2024-2025 | Erleada, Akeega, Balversa |
| Stemline Therapeutics INC. | $87.86 | 2025 | Orserdu |
| Geron Corporation | $79.25 | 2025 | Rytelo |
| Beigene USA, INC. | $78.92 | 2024-2025 | Brukinsa |
| Gilead Sciences, INC. | $77.44 | 2025 | Trodelvy |
| Incyte Corporation | $76.83 | 2025 | Jakafi, Monjuvi, Zynyz |
| Emd Serono, INC. | $73.35 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $73.14 | 2025 | Orgovyx |
| Coherus Oncology, INC. | $64.33 | 2024-2025 | Loqtorzi |
| Bayer Healthcare Pharmaceuticals INC. | $58.92 | 2025 | |
| Astellas Pharma US INC | $55.95 | 2024 | Xospata, Padcev |
| Genmab U.S., INC. | $42.19 | 2025 | Epkinly |
| Celgene Corporation | $31.64 | 2024 | Reblozyl |
| Agios Pharmaceuticals, INC. | $22.14 | 2025 | Pyrukynd |
| Glaxosmithkline, LLC. | $18.94 | 2025 | Jemperli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Tieu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.